Dronedarone in Atrial Fibrillation – Jekyll and Hyde?

Link to article at PubMed

Dronedarone in Atrial Fibrillation - Jekyll and Hyde?

N Engl J Med. 2011 Nov 14;

Authors: Nattel S

Atrial fibrillation, the most common type of sustained cardiac arrhythmia, is associated with increased morbidity and mortality and is often therapeutically challenging.(1) Dronedarone is a recently introduced antiarrhythmic drug that was developed by modifying the structure of amiodarone in an effort to reduce toxicity and improve pharmacokinetic properties.(1) Dronedarone has properties of all of the major classes of antiarrhythmic drugs.(1) In the ATHENA trial (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter; ClinicalTrials.gov number, NCT00174785),(2) dronedarone . . .

PMID: 22082122 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.